NICE Endorses Novo Nordisk’s Wegovy for Obesity

The UK’s National Institute for Health and Care Excellence (NICE) is recommending that the National Health Service (NHS) provide Novo Nordisk’s Wegovy (semaglutide) to obese adults.

The institute recommended that Wegovy only be offered for a maximum of two years. The recommendation is currently in draft form and NICE is accepting comments until March 1.

Management of overweight and obesity is “one of the biggest challenges our health service is facing with nearly two-thirds of adults either overweight or obese,” the institute said.